News | June 08, 2009

Percutaneous Value Replacement is an Option for Elderly Who May Not Survive Open-Heart Surgery

June 8, 2009 - Patients unable to undergo open-heart surgery may be candidates for a new nonsurgical aortic valve replacement procedure, according to a study presented at the 20th Annual Scientific Sessions of the American Society of Echocardiography (ASE) being held this week in Washington, D.C..

Transcatheter aortic valve replacement is a promising new treatment for patients with severe aortic stenosis who are considered high-risk for conventional surgical aortic valve replacement. With this approach, echocardiography, or heart ultrasound, is used to guide interventional cardiologists through the procedure and to assess the effects of intervention after the procedure. While this study showed promising results, the FDA has not yet approved transcatheter procedures for aortic valve replacement.

“Some people with severe aortic stenosis, or narrowing of the aortic valve, are not good candidates for open-heart surgery, because they may have other medical conditions that would classify them as high risk for surgery,” said Dr. Linda D. Gillam of the Columbia University Medical Center in New York, a lead author on the study. “This less invasive approach proved to be as effective as surgical aortic valve replacement with the patients in the study and can be done in a cath lab with less stress to the patient and a shorter recovery period.”

A total of 24 patients with symptomatic aortic stenosis underwent successful transcatheter aortic valve replacement or surgical aortic valve replacement during the study. There were no significant baseline differences between the two approaches. The study concluded that transcatheter and surgical aortic valve replacement result in comparable improvements in radial strain, strain rate and left ventricular ejection fraction in elderly patients with severe symptomatic aortic stenosis.

“People in their 80s have a 5-10 percent mortality rate when undergoing surgery for aortic valve replacement,” Gillam said. “These findings are especially critical for elderly patients who could not survive open-heart surgery.”

The study was conducted by Kotaro Arai, Eiichi Hyodo, Rebecca T. Hahn, Weihong Li, Kohei Fujimoto, Roy Pizzarello, Susheel Kodali, Mathew Williams, Martin B. Leon, Shunichi Homma, and Linda D. Gillam at Columbia University Medical Center in New York, NY.

The American Society of Echocardiography (ASE) is a professional organization of physicians, cardiac sonographers, nurses and scientists involved in echocardiography, the use of ultrasound to image the heart and cardiovascular system.

For more information: www.asecho.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now